Greenland Mines closed at $3.57 on Nov 5, down 8.70%, 76.0% below its highest close since Sep 11. Volume of 763.8K shares was 0.23× its 20-day average (below normal).
Split-adjusted performance: -38.8% over one month.
Short interest was 3.1M shares at the Oct 15 settlement, up 229.6% from the prior report (76.3% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GRMLGreenland Mines | $3.57 | −8.70% | — | — | — | — | $48.9M | |
| TILInstil Bio | $6.99 | 0.00% | −13.0% | — | — | — | $47.4M | Compare |
| IMAImageneBio | $4.17 | +1.59% | −29.5% | — | — | — | $47.3M | Compare |
| INKTMiNK Therapeutics | $10.05 | −5.19% | −10.2% | — | — | — | $51.3M | Compare |
| ELOXEloxx Pharmaceuticals | $12.80 | +0.47% | — | — | — | — | $51.7M | Compare |
| CRBUCaribou Biosciences | $0.4123 | −7.22% | −78.1% | −43.8% | −1619.9% | — | $44.2M | Compare |
| KLRSKalaris Therapeutics | $2.36 | +16.83% | −54.2% | — | — | — | $56.2M | Compare |
| LONALeonaBio | $4.34 | −4.93% | −56.0% | — | — | — | $40.9M | Compare |
| CRDFCardiff Oncology | $0.7553 | −13.07% | −52.8% | −14.0% | −8882.7% | — | $58.8M | Compare |
Greenland Mines Ltd is engaged in the exploration and development of mineral resources in Southeast Greenland. Its principal asset is the Skaergaard Project. The project hosts gold, palladium, and platinum mineralization, and the company is conducting drilling and development activities to evaluate and expand its mineral resources. It is also evaluating vanadium and gallium as potential additional mineral resources.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
